Celsion Corporation (NASDAQ: CLSN) to Ring The NASDAQ Stock Market Closing Bell

ADVISORY, July 15, 2014 (GLOBE NEWSWIRE) --

What:

Celsion Corporation (Nasdaq:CLSN), a leading oncology drug development company, will visit the NASDAQ MarketSite in Times Square.

In honor of the occasion, Michael Tardugno, Chief Executive Officer will ring the Closing Bell.

Where:

NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Wednesday, July 16, 2014 – 3:45 p.m. to 4:00 p.m. ET

Celsion Corporation Media Contact: Jeffrey W. Church Sr. Vice President and CFO 609-482-2455 jchurch@celsion.com

NASDAQ MarketSite: Christine Barna (646) 441-5310 Christine.Barna@nasdaqomx.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq.

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.

For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/.

Webcast:

A webcast of the NASDAQ Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx.

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About Celsion Corporation (Nasdaq:CLSN):

Celsion is fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer. The pipeline also includes EGEN-001, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has three platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlasTM, TheraSilenceTM and RASTTM. For more information on Celsion, visit our website: http://www.celsion.com.

About NASDAQ OMX Group

NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.

-NDAQA-

Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Aug 2024 to Sep 2024